Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trilaciclib myelopreservation with paclitaxel + carboplatin in advanced ovarian cancer
ChiCTR2500097713Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) comparing Trilaciclib group with Placebo group (2 arms). Primary endpoint: Incidence of grade 3 or higher neutropenia. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
trilaciclib
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on ChiCTR2500097713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500097713.